BioLineRx Ltd.
- Nasdaq
- BLRX
- CIK
- 1498403
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Israel
- Fiscal year ends
- December 31
- SEC filer category
- Non-accelerated filer
Key figures
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | $1.18M | $28.9M | $4.80M | – | – |
| Operating income | −$10.3M | −$20.4M | −$49.7M | −$29.2M | −$24.8M |
| Net income | −$2.03M | −$9.22M | −$60.6M | −$25.0M | −$27.1M |
| Diluted EPS | $0.00 | −$0.01 | −$0.06 | −$0.03 | −$0.04 |
| Cash from operations | −$8.07M | −$43.9M | −$22.6M | −$26.2M | −$23.6M |
| Total assets | $40.9M | $38.9M | $63.9M | $76.4M | $81.4M |
| Shareholders’ equity | $18.2M | $13.5M | $13.2M | $50.8M | $68.1M |
From the company’s annual reports to the SEC. Each year links to its report.
Financials 25
- 20-F/A Annual report (foreign issuer) for period ending Dec 31, 2025
- 20-F Annual report (foreign issuer) for period ending Dec 31, 2025
- 20-F Annual report (foreign issuer) for period ending Dec 31, 2024
- 20-F/A Annual report (foreign issuer) for period ending Dec 31, 2023
- 20-F Annual report (foreign issuer) for period ending Dec 31, 2023
- 20-F Annual report (foreign issuer) for period ending Dec 31, 2022
- 20-F/A Annual report (foreign issuer) for period ending Dec 31, 2021
- 20-F Annual report (foreign issuer) for period ending Dec 31, 2021
- 20-F Annual report (foreign issuer) for period ending Dec 31, 2020
- 20-F Annual report (foreign issuer) for period ending Dec 31, 2019
News 402
- 6-K Current report (foreign issuer)
- 6-K Current report (foreign issuer)
- 6-K Current report (foreign issuer)
- 6-K Current report (foreign issuer)
- 6-K Current report (foreign issuer)
- 6-K Current report (foreign issuer)
- 6-K Current report (foreign issuer)
- 6-K Current report (foreign issuer)
- 6-K Current report (foreign issuer)
- 6-K Current report (foreign issuer)
Ownership 66
- SCHEDULE 13G Major shareholder report (passive investor)
- 3 Initial statement of insider ownership
- 3 Initial statement of insider ownership
- 3 Initial statement of insider ownership
- 3 Initial statement of insider ownership
- 3 Initial statement of insider ownership
- 3 Initial statement of insider ownership
- 3 Initial statement of insider ownership
- 3 Initial statement of insider ownership
- 3 Initial statement of insider ownership
Prospectus 52
- 424B3 Prospectus filed pursuant to Rule 424(b)(3)
- 424B5 Prospectus filed pursuant to Rule 424(b)(5)
- S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
- 424B5 Prospectus filed pursuant to Rule 424(b)(5)
- 424B5 Prospectus filed pursuant to Rule 424(b)(5)
- 424B5 Prospectus filed pursuant to Rule 424(b)(5)
- S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
- 424B5 Prospectus filed pursuant to Rule 424(b)(5)
- 424B5 Prospectus filed pursuant to Rule 424(b)(5)
- S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Other 75
- EFFECT Notice of Effectiveness
- F-1 Registration statement for securities of certain foreign private issuers
- D Exempt (Private) Offering
- EFFECT Notice of Effectiveness
- F-3 Registration statement for specified transactions by certain foreign private issuers
- CT ORDER Order Granting Confidential Treatment
- EFFECT Notice of Effectiveness
- POS AM Post-effective amendment to a registration statement that is not immediately effective upon filing
- EFFECT Notice of Effectiveness
- CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.